Accessibility Menu
Actavia Life Sciences logo

Actavia Life Sciences(OTC) RASP

Current Price$0.00
Market Cap$385.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-99%
1 Year-88%
1 Month-95%
Actavia Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002025-12-26
Actavia Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-95%USD 0.012025-12-09
1 month-95%USD 0.012025-08-28
3 month-95%USD 0.012025-08-28
Year to date-87.5%USD 0.002024-12-31
1 year-87.5%USD 0.002024-09-11
3 year-91.8%USD 0.012022-11-22
5 year-99.17%USD 0.062020-12-22
Since inception-99.95%USD 1.102016-10-14

Actavia Life Sciences Financials at a Glance

Market Cap

$385.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$407.01K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-133.07 (Low)

Price

$0.00

Volume

20,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Jun 28, 2025

RASP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Actavia Life Sciences

Actavia Life Sciences, Inc. is a biotechnology company focused on developing therapeutic solutions for various forms of leukemia and lymphoma. Established in 2013 and headquartered in New York, the company emphasizes small molecule drug candidates, particularly for acute myeloid leukemia.

Products and Services
  • Therapeutic solutions for leukemia and lymphoma
  • Development of small molecule drug candidates
  • Research and development in oncology
Growth Outlook
  • Focus on expanding therapeutic offerings in oncology
  • Potential market growth driven by increasing leukemia cases
  • Investment in R&D to enhance drug development capabilities
Financial Highlights
  • Recent quarterly net income of -$95,518
  • Trailing twelve months (TTM) revenue of $0
  • Current liabilities significantly exceed current assets
Actavia Life Sciences, Inc. operates in a critical sector of healthcare, addressing significant unmet needs in cancer treatment. The company's focus on leukemia and lymphoma positions it well within a growing market, as the incidence of these diseases continues to rise. The emphasis on small molecule drug candidates reflects a strategic approach to developing innovative therapies that could potentially improve patient outcomes. Despite recent financial challenges, including a net income loss in the latest quarter, the company remains committed to advancing its research and development efforts. The lack of revenue highlights the early-stage nature of the business, which is common in biotechnology firms focused on long-term drug development. The current liabilities exceeding assets indicate a need for careful financial management as the company navigates its growth trajectory. Investors may find interest in Actavia Life Sciences, Inc. due to its specialized focus and the potential for future growth in the oncology market. The ongoing commitment to research and development could lead to breakthroughs that not only enhance the company's portfolio but also contribute positively to the healthcare landscape.
AI Generated • Jul 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Kunwar Shailubhai, PhD, MBA

Website

www.rasna.com

Headquarters

New York City, NY 10170, US

RASP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

243.82%

Return on Capital

N/A

Return on Assets

-4644.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$385.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

771.81M

Volume

20.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$345.54K

EBITDA

-$305.08K

Operating Cash Flow

-$66.42K

Capital Expenditure

$4.00

Free Cash Flow

-$66.42K

Cash & ST Invst.

$1.39K

Total Debt

$303.96K

Actavia Life Sciences Performance Analysis

Actavia Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 0N/A
20222022-09-30USD 0N/A
20232023-09-30USD 0N/A
Actavia Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-06-30N/A
Q42023-09-30N/A
Q12023-12-31N/A
Q22024-03-31N/A
Actavia Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD -0.01N/A
20222022-09-30USD -0.01-51.2%
20232023-09-30USD -0.0124.2%
Actavia Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-06-3098.6%
Q42023-09-30N/A
Q12023-12-31-100.0%
Q22024-03-3150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$385.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$385.90K

N/A

Employees

1

N/A

Net Income

-$95.52K

+97.7%

EBITDA

-$70.94K

-1113.4%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$1.39K

-37.3%

Total Debt

$303.96K

+37.9%

Accounts Receivable

$47.22K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$303.96K

+37.9%

Return on Assets

-46.45%

N/A

Return on Invested Capital

2.17%

N/A

Free Cash Flow

-$35.79K

-50.6%

Operating Cash Flow

-$35.79K

-50.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIRXViracta Therapeutics, Inc.
$0.01+0.00%
PDMIParadigm Medical Industries, Inc.
$0.00+0.00%
RSPIRespireRx Pharmaceuticals Inc.
$0.00+0.00%
NBIONascent Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About RASP

What is the current price of Actavia Life Sciences?

Actavia Life Sciences is trading at $0.00 per share.

What is the 52-week range for Actavia Life Sciences?

Over the past 52 weeks, Actavia Life Sciences has traded between $0.00 and $0.01.

How much debt does Actavia Life Sciences have?

As of the most recent reporting period, Actavia Life Sciences reported total debt of $210.98K.

How much cash does Actavia Life Sciences have on hand?

Actavia Life Sciences reported $74.99K in cash and cash equivalents in its most recent financial results.

What is Actavia Life Sciences’s dividend yield?

Actavia Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services